Madison Muller

This is Madison in New York with a special edition of the Prognosis newsletter. I’m worried the people in Los Angeles.

Drugmaker Eli Lilly & Co. has asked the US government to pause its forward march with drug-price negotiations, potentially thwarting the Biden administration’s plans to release a new list of drug targets before leaving office next week.

Hi! It’s Madison at the JPMorgan Healthcare Conference in San Francisco. Weight-loss drugs have been dominating the news cycle and 2025 will be no different. More on that in a moment ...

Eli Lilly & Co. reported preliminary fourth-quarter revenue that missed analyst estimates on lower-than-expected sales of its weight-loss and diabetes shots.

(Bloomberg) -- Eli Lilly & Co. reported preliminary fourth-quarter revenue that missed analyst estimates on lower-than-expected sales of its weight-loss and diabetes shots. Most Read from BloombergThese Homes Withstood the LA Fires. Architects Explain WhyA Blueprint for Better Bike LanesFourth-quarter sales are expected to be $13.5 billion, Lilly said Tuesday in a statement, below the $14 billion average estimate of analysts surveyed by Bloomberg. Both Zepbound for obesity and Mounjaro for diabe

Hi all, it’s Damian, Madison, Naomi, Gerry and Bob, and we all spent last week in San Francisco at the JPMorgan Healthcare Conference searching for decent Wi-Fi, dodging Waymos and overpaying for drinks.

A group of lawmakers are urging President Donald Trump to reject pharmaceutical companies' efforts to pause the Biden administration's drug-price cuts.

Abbott Laboratories is forecasting profit for 2025 in line with Wall Street’s estimates as the health care company said strong demand for its medical devices will continue to drive growth.

Abbott Laboratories is forecasting lower-than-expected first-quarter earnings but full-year profit in line with Wall Street estimates as the health care company points to strong demand for its medical devices as a growth driver this year.

Abbott Laboratories is forecasting lower-than-expected first-quarter earnings but full-year profit in line with Wall Street estimates as the health